immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker
HER2-positive Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.antibody_drug_conjugatePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
170 Active assets in the HER2-positive Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Eloxatin Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
DEXAMETHASONE Janssen Research & Development, LLC | Phase 2 | BBB |
Ipilimumab 7 Hills Pharma, LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →